Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994406 · ClinicalTrials.gov registry record · Phase 2
Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
A Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03994406 is a Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder that has completed, run by Glia. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03994406, a Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.
Conditions Studied
Interventions
- DRUG CLM2 topical gel
- DRUG Placebo topical gel
Study Locations (1)
California
- UC Berkeley Clinical Research Center - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03994406
The ClinicalTrials.gov registry entry for NCT03994406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Contact Lens Discomfort appearing as the primary indexed condition, and to 2 interventions - of which CLM2 topical gel is the first listed.
NCT03994406 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03994406 about?
NCT03994406 is a clinical study titled "Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel". This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.
What is the current status of trial NCT03994406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-06-27. Estimated completion is 2019-10-30.
What conditions does trial NCT03994406 study?
This clinical trial studies the following conditions: Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining.
What interventions are being tested in trial NCT03994406?
The interventions under investigation include: CLM2 topical gel (DRUG), Placebo topical gel (DRUG).
Who is sponsoring clinical trial NCT03994406?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03994406 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Lens Discomfort
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Contact Lens Discomfort
All registered trials for this condition
Contact Lens-induced Corneal Disorder
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.